Advertisement

CHICAGO, June 23, 2011 /PRNewswire-FirstCall/ -- Mr. Ronald L. Chez, a private investor, filed an amended 13D for RepliGen Corporation (Nasdaq: RGEN) with the SEC.

RepliGen Corporation is a biopharmaceutical company focused on building an integrated company by developing and marketing innovative drugs that deliver the benefits of protein therapies in the fields of neurology and gastroenterology.  RepliGen has a core competency in the development and manufacturing of biologics products, which serve as the basis for the bioprocessing business. RepliGen has out-licensed certain biologics intellectual property, which provide an ongoing source of revenue. RepliGen's corporate headquarters are located in Waltham, Massachusetts.

Mr. Ronald L. Chez is the President of Ronald L. Chez, Inc., and a private investor.

Inquiry Contact:

Barry Fischer

(312) 580-2233

'/>"/>

SOURCE

Advertisement
Advertisement